The Dedham Group’s Post

Few drugs have gripped the American public, like GLP-1 weight-loss medications. The strong sales of GLP-1 drugs raise questions about how insulin pricing crackdowns will affect pipeline strategies and how biopharma manufacturers will address supply issues to support diabetes patients. In a recent BioSpace BioSpace article, The Dedham Group’s Manuel Jurado provides commentary on the connection between the GLP-1 and the insulin market. Check out the full article: https://ow.ly/Uhfc50RRFhb #GLP1 #Insulin #Biopharma #PharmaceuticalCompanies

Unlock the power of market access success with PULSE Analytics by The Dedham Group. https://ow.ly/YV4G50Su9aA Our robust dataset equips you to navigate market challenges with confidence. Learn how to proactively address emerging specialty market needs and optimize resource allocation for enhanced strategic planning. Connect with us today!

In the interview with Healthcare de Jure (Healthcare NOW Radio), The Dedham Group’s James Pisano delves into challenges in behavioral health coverage and treatment delivery and how changes in healthcare parity legislation, benefit design, and innovative models either reshape the behavioral health environment or fall short. He also discusses how understanding these barriers helps define commercial strategy and product launch planning. Check out the full podcast episode: https://ow.ly/WmlM50R4M6f. #Healthcare #HealthcareLegislation #HealthcareIndustry #BehavioralHealth #TreatmentDelivery

Few drugs have gripped the American public, like GLP-1 weight-loss medications. The strong sales of GLP-1 drugs raise questions about how insulin pricing crackdowns will affect pipeline strategies and how biopharma manufacturers will address supply issues to support diabetes patients. In a recent BioSpace BioSpace article, The Dedham Group’s Manuel Jurado provides commentary on the connection between the GLP-1 and the insulin market. Check out the full article: https://ow.ly/fM0k50RRFa6 #GLP1 #Insulin #Biopharma #PharmaceuticalCompanies

Data presented at this year’s ASCO conference reinforced the importance of patient identification. Dedham Partners Matthew Cunningham and Aaron McKeon-Fish provided an overview of the conference and the Merck + Moderna readouts for PharmaLive. Check out their insights here: https://ow.ly/oZsk50SileP

The Dedham Group stands as the premier pharmaceutical consultancy firm, renowned for its expertise in crafting, executing, and overseeing Patient Support Programs (PSPs). Partner with us for customized solutions that drive success. https://ow.ly/MoGa50REVy3

While its goal is to make drugs more affordable for patients and reduce overall drug expenditure, the FDA’s Drug Importation Program is fraught with significant challenges. The Dedham Group's Aaron McKeon-Fish shares what manufacturers need to know: https://ow.ly/WICN50Rpuz2. #HealthcareReform #DrugAffordability #PrescriptionDrugs #HealthcareCosts #PharmaIndustry

The FDA’s Drug Importation Program’s influence on pricing pressure will be modest at best for manufacturers. Here’s why: https://ow.ly/4VX250RojOM. #HealthcareReform #PrescriptionDrugs #HealthcareCosts #PharmaIndustry #DrugImportation #HealthcarePolicy

Data presented at this year’s ASCO conference reinforced the importance of patient identification. Dedham Partners Matthew Cunningham and Aaron McKeon-Fish provided an overview of the conference and the Merck + Moderna readouts for PharmaLive. Check out their insights here: https://ow.ly/uOb650SbjQ2